Document Detail


Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis.
MedLine Citation:
PMID:  21418785     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To evaluate long-term safety and efficacy of etanercept (ETN) in patients with rheumatoid arthritis (RA) without concomitant disease-modifying antirheumatic drug therapy.
METHODS: A total of 549 patients enrolled in this 5-year, open-label extension after completing 1 of 2 randomised controlled studies; all patients received ETN 25 mg twice weekly during the extension. Safety assessments included physical exams, adverse events (AEs), vital signs, laboratory tests, and autoantibody evaluations. Key efficacy endpoints included numbers of responders achieving the American College of Rheumatology (ACR) criteria, low disease activity scores, and disease remission.
RESULTS: Three hundred and eight (56%) patients completed the 5-year extension study. Total ETN exposure, including that received during the double-blind studies was 2212 patient-years. Withdrawals for efficacy- and safety-related reasons were 12% and 19%, respectively. The most common AE was upper respiratory infection (44%). Rates of serious infections decreased over the 5-year period; one case of suspected tuberculosis was reported. Rates of malignancies remained generally consistent during the 5-year period. There were no reports of demyelinating disease, serious blood dyscrasias, or opportunistic infections. The relationship between autoantibody titres and clinical events was not statistically significant. Less than 5% of patients tested positive for anti-etanercept antibodies and all antibodies were non-neutralising. After 5 years, ACR 20, 50, and 70 response rates were 78%, 51%, and 32%, respectively; the mean percentage of patients achieving low disease activity score (DAS ≤ 2.4) and remission (DAS ≤ 1.6) were 44% and 20%, respectively.
CONCLUSIONS: ETN maintained a favourable safety profile and consistent efficacy throughout the 5-year study duration.
Authors:
L Klareskog; Ma Gaubitz; V Rodríguez-Valverde; M Malaise; M Dougados; J Wajdula;
Related Documents :
2317985 - Functional changes in the antagonists after lengthening the agonists in cerebral palsy....
16685085 - Lateral epicondylitis: in vivo assessment of arthroscopic debridement and correlation w...
21135805 - Advances in the treatment of atrial fibrillation.
11476425 - Good clinical results but persisting side-to-side differences in calf muscle strength a...
23017275 - Laryngeal chondrosarcoma: repeated laser and radiofrequency ablation in the palliative ...
10917355 - Stereotactic radiosurgery of cerebral arteriovenous malformations with a multileaf coll...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2011-04-19
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  29     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2011 Mar-Apr
Date Detail:
Created Date:  2011-04-20     Completed Date:  2011-06-22     Revised Date:  2011-08-15    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  238-47     Citation Subset:  IM    
Affiliation:
Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. lars.klareskog@ki.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies / blood
Antirheumatic Agents / administration & dosage*,  adverse effects*,  immunology
Arthritis, Rheumatoid / drug therapy*,  immunology
Humans
Immunoglobulin G / administration & dosage*,  adverse effects*,  immunology
Patient Dropouts
Randomized Controlled Trials as Topic
Receptors, Tumor Necrosis Factor / administration & dosage*,  immunology
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies; 0/Antirheumatic Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 185243-69-0/TNFR-Fc fusion protein
Investigator
Investigator/Affiliation:
Alonso Ruiz / ; D Andersone / ; J M Aranburu / ; P A Bacon / ; P Benito Ruiz / ; H J Bergerhausen / ; P Bertin / ; U Botzenhardt / ; H Bird / ; J Bratt / ; L Carreno / ; J Castenhag / ; G Chales / ; R Dahl / ; B Danneskiold-Samsoe / ; M Dougados / ; G Ferraccioli / ; M Figueroa / ; O Forre / ; S Friesleben Sorensen / ; M Gaubitz / ; J Gijon / ; J J Gomez Reino / ; J Goobar / ; N Graudal / ; H Haentzschel / ; G Hein / ; J R Kalden / ; J P Kaltwasser / ; J L Kuntz / ; H Lang / ; I Leden / ; B Lindell / ; M Malaise / ; E Martin Mola / ; O Meyer / ; N Misiuniene / ; M Mousa / ; H Nielsen / ; M Nissila / ; H Nusslein / ; T Helve / ; O Karjalainen / ; L Klareskog / ; M Korpela / ; R Luukkainen / ; J L Marenco / ; R Oding / ; J L Pasquali / ; E Rankin / ; V Rodriguez Valverde / ; J Sany / ; L Sköldstam / ; G Simenon / ; J G Tebib / ; J Tornero / ; S Transo / ; M Vallgarda Ojlert / ; H Warnatz / ; D Wendling / ; A Wittenborg / ; H Zeidler /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aspects of allergy in rheumatology.
Next Document:  Polymorphism in the promoter of the CCL5 gene (CCL5G-403A) in a cohort of North Indian children with...